EPCAM and nasopharyngeal carcinoma: However, CAR-T cells targeting the epithelial cell adhesion molecule (EpCAM), natural killer group 2 member D ligand (NKG2DL) and latent membrane protein (LMP1) remain in clinical trials to verify their safety and efficacy for the treatment of nasopharyngeal carcinoma.